Free Trial
NYSE:ANRO

Alto Neuroscience (ANRO) Stock Price, News & Analysis

Alto Neuroscience logo
$3.70 -0.11 (-2.76%)
Closing price 08/29/2025 03:58 PM Eastern
Extended Trading
$3.68 -0.02 (-0.65%)
As of 08/29/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alto Neuroscience Stock (NYSE:ANRO)

Key Stats

Today's Range
$3.52
$3.85
50-Day Range
$2.21
$4.14
52-Week Range
$1.60
$15.04
Volume
89,958 shs
Average Volume
99,464 shs
Market Capitalization
$100.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Moderate Buy

Company Overview

Alto Neuroscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

ANRO MarketRank™: 

Alto Neuroscience scored higher than 36% of companies evaluated by MarketBeat, and ranked 760th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alto Neuroscience has only been the subject of 1 research reports in the past 90 days.

  • Read more about Alto Neuroscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Alto Neuroscience are expected to grow in the coming year, from ($2.54) to ($2.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alto Neuroscience is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alto Neuroscience is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alto Neuroscience has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Alto Neuroscience's valuation and earnings.
  • Percentage of Shares Shorted

    10.00% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Alto Neuroscience has recently increased by 4.88%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Alto Neuroscience does not currently pay a dividend.

  • Dividend Growth

    Alto Neuroscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.00% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Alto Neuroscience has recently increased by 4.88%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Alto Neuroscience has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.08 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 23 news articles for Alto Neuroscience this week, compared to 6 articles on an average week.
  • Search Interest

    Only 3 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alto Neuroscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.13% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Alto Neuroscience's insider trading history.
Receive ANRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANRO Stock News Headlines

Buffett, Gates and Bezos Dumping Stocks
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.tc pixel
See More Headlines

ANRO Stock Analysis - Frequently Asked Questions

Alto Neuroscience's stock was trading at $4.23 at the start of the year. Since then, ANRO shares have decreased by 12.4% and is now trading at $3.7050.

Alto Neuroscience, Inc. (NYSE:ANRO) released its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.08.

Alto Neuroscience (ANRO) raised $129 million in an initial public offering on Friday, February 2nd 2024. The company issued 8,040,000 shares at a price of $16.00 per share.

Alto Neuroscience's top institutional shareholders include Armistice Capital LLC (6.00%), Marshall Wace LLP (3.46%), AWM Investment Company Inc. (1.04%) and Peapod Lane Capital LLC (1.03%). Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith.
View institutional ownership trends
.

Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/13/2025
Today
8/30/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ANRO
Previous Symbol
NYSE:ANRO
CIK
1999480
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$4.00
Potential Upside/Downside
+129.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$61.43 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-44.34%
Return on Assets
-36.73%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
18.43
Quick Ratio
18.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.56 per share
Price / Book
0.81

Miscellaneous

Outstanding Shares
27,080,000
Free Float
24,063,000
Market Cap
$100.33 million
Optionable
N/A
Beta
1.84

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NYSE:ANRO) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners